Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. [electronic resource]
Producer: 20070803Description: 637-48 p. digitalISSN:- 0011-9059
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Dermatologic Agents -- adverse effects
- Drug Administration Schedule
- Female
- Humans
- Injections, Subcutaneous
- Male
- Middle Aged
- PUVA Therapy
- Psoriasis -- drug therapy
- Secondary Prevention
- Severity of Illness Index
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.